KRAS and non-small cell lung carcinoma: Occurring in approximately 13% of NSCLC and >1% of colorectal cancer and various other solid tumors, KRAS G12C mutations were found to be targetable in pre-clinical studies through irreversible, covalent binding of small molecule kinase inhibitors to the mutated cysteine and nearby P2 pocket of the switch II region [193,194,195].